First Data Chairman and CEO Michael Capellas to Speak at Credit Suisse 2008: Annual Technology Conference
26.11.08 - 00:22 ... source : First Data
... DENVER, Nov 25, 2008 50BUSINESS WIRE 51 -- First Data today announced that on Tuesday, December 2, Michael Capellas, chairman and chief executive officer, will participate in the Credit Suisse 2008 Annual Technology Conference at The Phoenician in Scottsdale, Arizona. Capellas will be the Keynote Speaker from 12:15 to 1:30 p.m. Mountain Standard Time. 240240In order to access the webcast, please go to http://ir.firstdatacorp.com/events.cfm web approximately 15 minutes prior to the start ...» Next (PDF)
Similar news
94% | 18.11.08 - 07:31 ... source : California Lutheran University
... 2008 01:58 pm PST Michael Towbes, owner and chairman of The Towbes Group, will give a presentation about banking and real estate development titled "A View From Both Sides of the Fence." (THOUSAND OAKS, Calif. - Nov. 17, 2008) A ...
92% | 19.11.08 - 19:03 ... source : AT&T
... next-generation utility computing services for businesses Dallas, Texas, November 19, 2008 Singapore — AT&T Inc. (NYSE:T) today announced it is opening the first super Internet Data Centre (IDC) in Asia, located in Singapore. The super IDC, an expansion of AT&T's ...
91% | 14.11.08 - 21:28 ... source : New York Stock Exchange
... pre- and post-market stock prices- -Most comprehensive package of online stock market data- NEW YORK , Nov. 14, 2008 – NYSE Arca last-trade data is now available online from CNBC , First in Business Worldwide, and Google Finance, thereby broadening ...
91% | 14.11.08 - 18:08 ... source : First Data
... 45DENVER, November 14, 2008 - First Data Corp. today reported its financial results for the third quarter of 2008. Consolidated revenues were up 4 45 to $2.2 billion. The adjusted earnings before interest, taxes, depreciation and amortization 50EBITDA 51 were ...
90% | 08.11.08 - 08:42 ... source : Molecular Insight Pharmaceuticals
... (NASDAQ: MIPI) announced today that it will present results from a prospective analysis of Phase 2b data (BP-21) for its lead molecular imaging radiopharmaceutical candidate, Zemiva, as a poster at the 2008 Scientific Sessions of the American Heart Association in ...
